Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 4, 2026 by admin

A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398

Conditions: Schizophrenia Disorder

Interventions: Drug: SIPI6398 Tablets

Sponsors: Shanghai Zhongze Therapeutics Co., Ltd.; Yale University

Not yet recruiting
CategoriesClinicalTrials.gov TagsAcademic research, Fear and threat response, Medication, Mood and emotional regulation, News Approved, Schizophrenia spectrum

Post navigation

Previous PostPrevious Transcranial Temporal Interference Stimulation for Children With Autism Spectrum Disorders
Next PostNext A Prospective Comparative Study Evaluating the Safety and Efficacy of Transurethral Thulium Fiber Laser, Holmium Laser and Bipolar Enucleation of Large Sized Prostate
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.